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Regulation of fibroblast proliferation <p>Global transcriptional profiling of human fibroblasts from two different tissue sources reveals distinct as well as conserved responses  to different growth stimuli.</p>
Abstract
Background:  Serum treatment of quiescent human dermal fibroblasts induces proliferation,
coupled with a complex physiological response that is indicative of their normal role in wound-
healing. However, it is not known to what extent such complex transcriptional events are specific
to a given cell type and signal, and how these global changes are coordinately regulated. We have
profiled the global transcriptional program of human fibroblasts from two different tissue sources
to distinct growth stimuli, and identified a striking conservation in their gene-expression signatures.
Results: We found that the wound-healing program of gene expression was not specific to the
response of dermal fibroblasts to serum but was regulated more broadly. However, there were
specific differences among different stimuli with regard to signaling pathways that mediate these
transcriptional programs. Our data suggest that the PI3-kinase pathway is differentially involved in
mediating the responses of cells to serum as compared with individual peptide growth factors.
Expression profiling indicated that let7 and other miRNAs with similar expression profiles may be
involved in regulating the transcriptional program in response to proliferative signals.
Conclusion:  This study provides insights into how different stimuli use distinct as well as
conserved signaling and regulatory mechanisms to mediate genome-wide transcriptional
reprogramming during cell proliferation. Our results indicate that conservation of transcriptional
programs and their regulation among different cell types may be much broader than previously
appreciated.
Background
The transition of mammalian cells from quiescence to prolif-
eration and their re-entry into the cell cycle (the G0 to G1
transition) underlies diverse normal physiological processes,
such as tissue regeneration, wound healing and lymphocyte
activation, and it is also one of the hallmarks of cancer [1-3].
This transition is marked by activation of cell-surface recep-
tors, intracellular signal transduction pathways and effector
transcription factors, which in turn lead to altered programs
of gene expression, driving cells into the proliferative state.
The molecular mechanisms governing this transition are
believed to be distinct from those of other cell cycle transi-
tions such as the G1 to S transition, and are less well charac-
terized [4]. One key question is, to what extent are the
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regulatory pathways and transcriptional programs of re-entry
into the proliferative state shared by different types of cells
responding to different mitogenic signals? What is the inter-
play of these proliferative responses with the innate cell and
tissue-type characteristics of cells?
Fibroblasts have long been used as a simple model to study
mammalian cell proliferation in culture. The global transcrip-
tional program of quiescent human dermal fibroblasts stimu-
lated to proliferate by serum treatment indicates that there is
a complex physiological wound-healing response that is
superimposed upon the expected proliferative response [5].
Fibroblasts derived from different anatomical sites display
characteristic expression patterns reflective of their site of
origin [6]. Interestingly, the genes affected during the prolif-
erative response of cultured fibroblasts to serum are predic-
tive of tumor prognosis and metastasis in different cancers
[7], implying that a conserved core set of regulatory mecha-
nisms underlies the transition to proliferation in diverse cell
types. On the other hand, gene expression analysis of cultured
human fibroblasts from skin, lymph node, synovium and ton-
sil revealed heterogeneity in their expression profiles [8].
Despite these studies, however, little is known about the dif-
ferences between the response of fibroblasts to serum versus
other individual growth factors (GFs), both in terms of global
transcriptional programs and the signal transduction path-
ways that are affected by each stimulus. It is unclear, there-
fore, if the complex mixture of components present in serum
is required to trigger the wound healing response observed in
skin fibroblasts. It is also not known if other types of fibrob-
lasts that do not have an obvious role in surface wound heal-
ing and are not typically exposed to serum in the body are
nevertheless capable of carrying out a similar program of
gene expression. The connection between the G0 to G1 prolif-
erative response and the physiological wound healing
response is also not clear. For example, AP-1 is involved in cell
cycle progression but it also targets genes in fibroblasts
important for wound healing [9].
We address some of these questions in this study by analyzing
the genome-wide transcriptional reprogramming of fibrob-
lasts derived from skin as well as lung, when they are stimu-
lated to proliferate either by serum or purified growth factors.
We also dissect the contribution of specific signaling path-
ways to these global responses using an inhibitor of the PI3-
kinase (PI3K) pathway. Finally, we have begun to analyze the
potential involvement of micro RNAs (miRNAs) that have
recently been shown to be involved in gene regulation in can-
cer models, in regulating the transition of normal quiescent
diploid cells into the proliferative state.
Results
Experimental strategy
We profiled the response of two normal human diploid
fibroblast cell lines to either serum or three different peptide
GFs. One of the cell lines was a foreskin-derived dermal
fibroblast (2091) and the other was a fetal lung-derived pul-
monary fibroblast line (WI-38) [10]. Cells were first deprived
of growth factors by growing them in medium containing
0.1% fetal bovine serum (FBS) for 48 hours, then treated with
medium containing either 10% FBS, epidermal growth factor
(EGF), fibroblast growth factor (FGF) or platelet derived
growth factor (PDGF). Cells were harvested at 6 different
time points (0 h, 0.5 h, 1 h, 2 h, 4 h, 8 h), followed by total
RNA isolation and RNA amplification (Figure 1a). Temporal
global transcription profiles were measured using cDNA
microarrays containing 46,544 clones, corresponding to
approximately 31,158 unique Unigene clusters [11,12]. RNA
from each sample of cells was reverse transcribed to cDNA
and labeled with Cy5, and hybridized to the cDNA microar-
rays together with a universal human reference sample
labeled with Cy3.
Experimental set up and overall expression profiles Figure 1 (see following page)
Experimental set up and overall expression profiles. (a) The time course of gene expression was determined during the response of two different 
fibroblast types; 2091 derived from foreskin and WI-38 derived from fetal lung. Each was treated with either the indicated GFs, epidermal growth factor 
(EGF), fibroblast growth factor (FGF), platelet derived growth factor (PDGF) or FBS (Serum), and three replicate time courses were run for each 
treatment. The layout of the samples in the other panels as well as in Figures 2-6 is as shown here. (b) Hierarchical cluster of 1,304 genes with a minimum 
expression change of twofold in at least 15 array experiments and with data present in at least 80% of all array samples. cDNAs with no known Unigene 
annotation or mapping to multiple Unigene clusters were removed. Black bars on the right indicate consistently induced genes. (c) Sub-cluster branches 
containing the consistently induced genes were selected and re-clustered. This set included 237 genes represented by 278 cDNA probes. (d) Consistently 
repressed genes were selected directly from expression data as described in Materials and methods and clustered. This set included 237 genes 
represented by 250 cDNA probes.http://genomebiology.com/2006/7/5/R42 Genome Biology 2006,     Volume 7, Issue 5, Article R42       Gu and Iyer  R42.3
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2006, 7:R42
Figure 1 (see legend on previous page)
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To identify consistent expression changes caused by each
stimulus, we performed three independent biological repli-
cates of each treatment for each cell line (Figure 1a). In most
cases, we isolated at least two independent time zero samples
for each treatment time course and normalized all expression
changes relative to the average of the time zero values to min-
imize error arising from time zero measurements. All data
were uploaded to a relational database [13] and filtered on
basic data quality measures before further analysis. All pri-
mary data reported here are available at NCBI's GEO (Acces-
sion IDs GSE3901 and GSE3902) as well as at the authors
laboratory web site [14], and the ratio data tables for all gene
sets described here are available as accompanying Additional
data files. A small subset of the expression changes we
observed were not reproducible across all three repeats for
each treatment. To ensure that we analyzed only data that was
biologically reproducible, the results and discussion pre-
sented here pertain to only those changes that were consist-
ent across the three biological replicate time-courses of a
given combination of cell line and treatment. Three classes of
genes will be discussed in the following sections. Class I refers
to genes that were consistently induced or repressed across all
the serum and GF treatments. Class II refers to genes that
were differentially expressed in response to serum and the GF
treatments. Class III genes are those that were differentially
expressed between the two fibroblast cell lines.
The expression of wound healing genes is affected by all 
treatments and is not specific to serum
We used hierarchical cluster analysis to obtain a bird's-eye
view of the global expression patterns (Figure 1b). Strikingly,
there were no prominent sets of genes that were consistently
and uniquely regulated by a given treatment. However, genes
showing statistically significant differences in expression
between serum treatment and the three other GF treatments
could be identified through the use of a t test (Class II). These
treatment-specific responses are described in a later section,
as are the genes that show differences in response between
the two cell types (Class III). We identified a group of 237
genes, represented by 278 cDNA probes, that were concord-
antly induced by serum and each of the three different growth
factors (Figure 1c). To identify genes consistently repressed
by all four treatments, we selected genes whose expression
was lower after stimulation than in the time zero samples in
at least 85% of arrays. This identified a set of 237 genes rep-
resented by 250 cDNA probes (Figure 1d). Together, this set
of genes, which generally showed similar responses in both
cell types to all four treatments, is referred to as Class I (Addi-
tional data file 1).
Class I genes included known immediate-early genes such as
JUNB, MYC, PTGS2 and others. It has been previously noted
that in response to serum, fibroblasts show altered expression
of genes involved in cell proliferation, blood coagulation,
cytoskeletal reorganization, angiogenesis and inflammation -
all functions that are closely related to the physiology of
wound healing [5,7]. Surprisingly, our results indicate that
not only serum, but several other growth factors in isolation
affect the expression of a similar coherent set of genes rele-
vant to wound healing. We observed the altered expression of
several genes involved in cytoskeletal reorganization, tissue
remodeling, angiogenesis, blood coagulation and inflamma-
tion, as well as signal transduction pathways that mediate the
above processes (Figure 2). We used DAVID [15,16] to quan-
tify the enrichment of Gene Ontology (GO) terms in our gene
sets and noted significant enrichment of several of these cat-
egories (Additional data file 2). Moreover, the response of
lung fibroblasts with regard to the expression of these genes
could not be distinguished from the response of the skin
fibroblasts, indicating that the wound healing expression sig-
nature is not specific to the response of dermal fibroblasts to
serum.
The core conserved response of fibroblasts during the 
transition from quiescence to proliferation
The molecular pathways underlying the transition from qui-
escence to proliferation triggered by each of the four treat-
ments in both fibroblast types appeared to be strongly
conserved, as suggested by the altered expression of cyclin/
cdk related genes, such as CCNL1, CKS2, CDCA1, CDKN1B
and CDC25C, and genes involved in DNA replication, such as
TOP2A, PCNA and POLE3, across all treatments (Figure 2).
Interestingly, a group of genes related to cell cycle check-
points, such as BRCA1, RAD1 and RAD21, were repressed
(Figure 2), likely reflecting the requirement for the down-reg-
Functional groupings in consistently expressed genes Figure 2
Functional groupings in consistently expressed genes. Genes with 
consistent expression patterns across all treatments (Class I genes) were 
manually grouped into several functional categories as indicated, based on 
annotations from Unigene and GO.
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ulation or deactivation of these checkpoint proteins for either
cell cycle entry or progression. Genes with anti-apoptotic
function, such as BAG3 and TNFRSF10D, were upregulated
while others promoting apoptosis were inhibited in all the
treatments (Figure 1c). GADD45B, another induced gene, is
believed to have anti-apoptotic functions by downregulating
JNK signaling [17]. All these observations suggest that
reentry into the cell cycle by serum starved G0 cells requires
the upregulation of cell cycle related genes as well as inhibi-
tion of apoptotic signaling pathways.
Cell cycle progression from G0 to G1 is highly dependent on
the activation of intracellular signaling pathways. Growth fac-
tors are required at two critical points during the G0 to G1
transition to stimulate the MAP kinase (ERK) pathway, c-
Myc, and the PI3K pathway [18]. We observed altered expres-
sion of regulatory factors in the RAS-MAPK pathway and the
PI3K pathway, such as YWHAG (14-3-3- gamma) [19], SPRY2
[20], DUSP5 [21], DUSP6 [22], and PITPNC1 [23] (Figure 2).
This observation suggests that both signaling pathways are
involved in the response of fibroblasts but, interestingly, only
the MAPK pathway activation and c-Myc  induction are
believed to be indispensable during the early 0 to 8 hour
period of fibroblast response [18]. Our results also corrobo-
rate previous studies showing that different growth factors
may activate cell proliferation by largely overlapping mecha-
nisms that include the activation of these two signaling path-
ways [24]. The potential involvement of the JAK/STAT
pathway was indicated by the upregulation of its downstream
effectors, such as PIM1 [25], as well as the upregulation of
several SOCS genes, which are targets and negative feedback
regulators of this pathway [26]. Figure 3 shows the altered
expression of these genes overlaid on a schematic representa-
tion of the three signaling pathways whose activity is sug-
gested by this expression profiling data.
There were subtle differences among the induction patterns
of Class I genes even though they were consistently induced
by all four treatments. Although serum treatment generally
resulted in higher peak induction levels than the growth fac-
tor treatments, the majority of the induced genes peaked
eight hours after serum addition compared to 2 to 4 hours
after GF treatment (Additional data file 3). This could par-
tially be a result of differences in concentrations of the GFs
that were employed. Indeed, we found that increasing con-
centrations of FGF, ranging from 5 ng/ml to 135 ng/ml,
caused increasingly stronger induction of these genes at two
hours (Additional data file 4). However, the fact that serum
generally caused stronger induction of genes but with delayed
kinetics suggests that there are differences in the response of
fibroblasts to serum and the GFs such as those described
below or, possibly, that a combination of different growth fac-
tors and other components such as lysophosphatidic acid in
serum could contribute to the differences.
The PI3-kinase pathway is differentially involved in 
regulating the responses to serum versus individual 
growth factors
Since hierarchical clustering did not directly reveal genes
with expression differences specific to each treatment, we
used a supervised approach to identify genes whose average
expression levels were significantly different after treatment
among the different groups. Based on the fact that peak
expression levels were most different between serum treat-
ment and all the growth factor treatments, we used a t test to
identify genes that showed significant differential expression
between these two groups. This analysis identified 701
cDNAs, representing 619 genes, that tended to be induced fol-
lowing serum treatment but were repressed or remained
unchanged after GF treatment, and 613 cDNAs, representing
566 genes, that generally showed higher expression levels in
response to growth factors. These genes are termed Class II
genes and are described below (Additional data file 5).
Many Class II genes were those involved in signal transduc-
tion, suggestive of differences in signaling events between the
serum and GF responses. The EGF receptor gene EGFR was
induced by serum, while its negative regulator CBL - an E3-
ubiquitin ligase that targets EGFR and FGFR for degradation
[27] - was upregulated in the GF treatments (Figure 4), sug-
gesting a negative regulatory circuit. We observed a modest
increase in EGFR protein levels in response to serum com-
pared to the GF treatments (Figure 5a). However, EGF treat-
ment, but not PDGF or FGF, caused a marked down
regulation of EGFR protein levels, even though at the tran-
scriptional level the response of EGFR to the three different
growth factors was consistently similar. This is likely due to a
stronger induction of CBL by EGF compared to the other GF
treatments (Figure 5b), suggesting that the negative regula-
tory circuit involving CBL and EGFR is involved in mediating
the response to growth signals in these cells. Although we
could validate the expression levels and potential regulation
of EGFR at the protein level, there were cases where protein
levels did not reflect the changes in mRNA expression levels.
For example, H-RAS transcript levels were slightly induced in
GF treatments compared to serum. However, we failed to
detect any change in H-RAS protein expression levels (Figure
5a,b).
The PI3K pathway is believed to be involved during late G1
during the transition from quiescence to proliferation [18].
Some downstream components of PI3K signaling, such as
PIP5K3, were among the Class II genes that were induced by
serum, while others like ribosomal protein S6 kinase B6 and
AKT2 [28-30] were among the serum repressed Class II genes
(Figure 4). Diacylglycerol (DAG) produced by the activation
of the phosphoinositide pathway is the physiological activator
of protein kinase C (PKC) as well as other protein kinase C
conserved region 1 (C1)-domain proteins, such as protein
kinase D1 (PKD1), RasGRPs and DAG kinase gamma [31].
Diacylglycerol kinases (DGKs) terminate DAG-mediatedR42.6 Genome Biology 2006,     Volume 7, Issue 5, Article R42       Gu and Iyer  http://genomebiology.com/2006/7/5/R42
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signaling by converting DAG to phosphatidic acid (PA). Nine
DGK isoforms have been identified and classified into five
subgroups based on their structure, which, along with their
different subcellular localization, suggests distinct DAG sign-
aling events they may regulate [32]. DGKs, such as DGKA,
DGKD, and DGKZ, were among the serum repressed Class II
genes and PKC (PRKD3) was in the serum upregulated set.
Taken together, these observations suggested that the PI3K
signaling pathway may have a more prominent role in the
response to serum (Figure 4).
To test the hypothesis that the PI3K pathway is responsible
for some of the differences in the response of fibroblasts to
serum versus individual GFs, we treated cells with the PI3K
pathway inhibitor LY294002 and determined expression
profiles after growth stimulation. When the PI3K pathway
was inhibited, the response of Class II genes in the serum
treatment group switched to a pattern similar to that of the
GF groups, consistent with the notion that the PI3K signaling
pathway has a more prominent role in the response to serum
(Figure 6). This switch of Class II expression profiles from
serum-like to GF-like was specific to inhibition of the PI3K
pathway. When cells were treated with U0126 - a MEK inhib-
itor - prior to serum stimulation, we did not observe a similar
switch in expression profiles (Figure 6). However, the serum
response was almost completely abrogated after U0126 treat-
ment, consistent with a critical role for the MAP kinase path-
way in cell cycle reentry.
Signaling pathways activated by serum and GF treatments Figure 3
Signaling pathways activated by serum and GF treatments. Major components from three pathways, the PI3K pathway, the JAK/STAT pathway and the 
MAP kinase pathway are indicated. Class I genes with consistent expression profiles across all treatments in our experiments are indicated by red (up-
regulated) or green (down-regulated) at their appropriate position in each of the pathways.
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Identification of genes differentially expressed between 
cell lines
Fibroblasts from different anatomical sites tend to have char-
acteristic expression patterns related to their specific physio-
logical functions despite sharing similar morphology [6]. The
two fibroblast cell lines we used originate from different tis-
sue sources - skin and lung - and are thus expected to have
distinct transcription programs. During quiescence, namely,
at the zero-hour time point and in the absence of growth sig-
nals, lung-specific genes were expressed in the WI-38 cell line
derived from fetal lung whereas skin-specific genes were
expressed in the 2091 cell line derived from newborn foreskin
(Additional data file 6). To identify differences between the
responses of the two cell types to growth stimulation, how-
ever, we compared the relative expression ratios after stimu-
lation from all the experiments on the two cell lines using the
same method as described above. A set of 385 cDNA probes
representing 358 genes was found to be differentially
expressed between these two cell lines at a false discovery rate
(FDR) of 1% (Figure 7). This set of genes is denoted as Class
III (Additional data file 7).
Hierarchical clustering of the 385 Class III genes revealed two
broad patterns of differential expression between the two cell
types; 341 genes were generally more strongly induced in the
skin fibroblasts whereas only 4 4  g e n e s  w e r e  e x p r e s s e d  a t
higher levels in the lung fibroblasts (Figure 7a,b). This bias is
possibly due to the higher proliferative potential of the fore-
skin cells. Several genes related to cell proliferation, such as
CDC2,  CDK2AP1,  CDKN3  and  MCM6,  t e n d e d  t o  b e  m o r e
strongly induced in the skin cells. Several genes encoding cel-
lular receptors, such as erythropoietin receptor, GABA A
receptor, receptor tyrosine kinase-like orphan receptor 2,
chemokine orphan receptor 1, EGF and the ERBB2 receptor,
were included among the genes more strongly induced in the
skin fibroblasts relative to the lung fibroblasts (Figure 7a).
Only a few previously characterized skin-specific genes were
included among the genes more strongly induced in the skin
cells. One example of such a gene is TBX2, which remained
unchanged or showed slightly reduced expression in most
treatments of the lung cells. Interestingly, however, a few
lung signature genes, such as TBX2 and SOX4, were among
the genes induced to a greater extent in the foreskin cell line
(Figure 7a). Since these genes are expressed at much higher
Class II genes showing differential expression responses to serum versus  GFs Figure 4
Class II genes showing differential expression responses to serum versus 
GFs. Genes in this category were identified through the use of a t test with 
false discovery rate (FDR) less than 1%. The two groups for the t test 
were all the serum treated samples as one group, and all the GF treated 
samples as another. Genes involved in signal transduction, cholesterol 
biosynthesis, glutathione/peroxisome synthesis and transporters are 
indicated.
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A putative regulatory circuit involving EGFR Figure 5
A putative regulatory circuit involving EGFR. (a) Protein expression levels 
in skin fibroblasts 2 hours after treatment with serum or individual growth 
factors. Total protein extracts from treated cells were loaded equally on a 
gel followed by western blot analysis using EGFR, HRAS and ERBB2 
antibodies. (b) mRNA expression patterns for CBL, ERBB2, HRAS, SPRY2 
and EGFR across all growth stimulations in foreskin fibroblasts. EGFR 
mRNA is more strongly induced by serum compared to the GFs, but the 
induction of EGFR protein is only modest in response to serum. Its 
negative regulator, CBL, is more strongly induced at the RNA level in 
response to EGF, concordant with the strong down-regulation of EGFR 
protein in EGF treated cells.
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Figure 6 (see legend on next page)
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levels in lung than in foreskin, it is possible that their
induction is more easily detectable in the skin cells. Most lung
and skin specific genes did not show significant expression
changes during the transition from quiescence to prolifera-
tion, and it is likely that their expression levels remain con-
stant during the cell cycle.
miRNA profiling of skin fibroblasts in response to 
growth stimulation
We noticed that the set of Class I genes consistently induced
by all treatments included EIF2C2, a member of the Argo-
naute gene family and a component of the RISC complex
involved in post-transcriptional gene silencing by miRNAs
[33,34] (Figure 1c). Although miRNAs have recently been
shown to have a role in the proliferation of cancer cells and
stem cells [35-37], not much is known about their role in the
proliferative response of normal, differentiated quiescent
cells. We therefore performed expression profiling with
miRNA microarrays to explore the alterations in the expres-
sion levels of miRNAs in skin fibroblasts during their transi-
tion from quiescence to proliferation. miRNA was isolated
from asynchronously growing cells and from quiescent
fibroblasts, before and after growth stimulation. We carried
out a total of 18 miRNA microarray hybridizations using
miRNA from six independent biological samples and dye-
swap hybridizations. The overall expression changes in miR-
NAs were less dramatic compared to their expression differ-
ences reported in different human tissues [38]. We also noted
a higher degree of experimental variability within biological
repeats and dye-swap experiments, possibly due to the labe-
ling method we employed, which relies on adding dye modi-
fied nucleotides directly to the miRNAs. Dye quenching can
occur at sub-optimal densities of labeling, which results in
fluorescent dyes in close proximity to one another [39,40].
We identified a cluster of 33 miRNAs with similar and con-
sistent expression profiles across the replicates and dye-
swaps. This cluster of miRNAs was repressed in asynchro-
nously growing skin fibroblasts but they were induced early
during proliferation, both by serum as well as FGF. This clus-
ter includes a number of miRNAs belonging to the let-7 family
as well as several other miRNAs (Figure 8, Additional data file
8), suggesting that these miRNAs might be involved in regu-
lating the expression of target genes important for the reentry
of these cells into the cell cycle.
We used the PicTar program [41,42] to predict miRNA targets
based on sequence homology, optimal free energy, and
ortholog searching [41]; 31 of the 33 miRNAs were found in
the PicTar database. Predicted targets for these miRNAs with
a PicTar score greater than 4 comprised 1,246 unique Uni-
gene clusters. Functional annotation analysis using DAVID
revealed that genes involved in the MAP kinase pathway,
focal adhesion and GAP junctions were among the most
enriched Kegg pathways (p < 0.01). However, a similar anal-
ysis of targets for 31 random miRNAs also revealed an appar-
ent enrichment of MAP kinase pathway genes, so the
biological meaning of the enrichment of these categories in
the PicTar predicted targets of the serum induced miRNAs
remains unclear.
Discussion
The wound healing and cell proliferation response of 
human fibroblasts
The characteristic wound healing and proliferative response
of human dermal fibroblasts after serum treatment originally
suggested that this response reflected the obligatory in vivo
physiological response of dermal fibroblasts to serum factors
released upon wounding. Here we observe that not only der-
mal fibroblasts, but also lung fibroblasts, carry out a largely
conserved program of gene expression reminiscent of wound
healing, in response not only to serum but also individual
purified GFs. Although some aspects of this conserved
response could arise due to the similarity of culture condi-
tions, the fact that tissue-specific differences were main-
tained in quiescent fibroblasts even in culture suggests that
the wound healing response to ostensibly proliferative stimuli
is more broadly conserved across distinct fibroblast cell types
from different tissue sources and can be elicited by a variety
of triggers. Conceivably, the wound healing response origi-
nated initially in a dermal-like fibroblast and persisted in
other fibroblast types in other specialized tissues. Although it
is possible to speculate on the evolutionary reasons and
advantages of such a conserved gene expression program, the
mechanisms of how the program is initiated and regulated are
unclear. One possibility is that, in fibroblasts, the wound
healing and cell signaling programs are coupled to a large
extent to cell proliferation. In all the experiments in this study
and in several previous studies, the signals that trigger the
wound healing gene expression program also caused concom-
itant cell proliferation [43]. However, some agents such as
phenytoin can induce wound healing genes, including those
involved in tissue remodeling, inflammation, coagulation and
hemostasis in dermal fibroblasts, without inducing cell prolif-
eration, suggesting that the wound healing response does not
necessarily require cell proliferation [44]. Mechanical strain
in human scleral fibroblasts [45] can also induce similar
Role of the PI3K pathway in mediating differences between serum and GF response Figure 6 (see previous page)
Role of the PI3K pathway in mediating differences between serum and GF response. A cluster view of the 1,379 Class II clones showing differential 
expression between serum and other GF treatment groups is shown. The right hand side shows the expression profiles of these Class II genes in foreskin 
fibroblasts when quiescent cells were first treated with either LY294002 (a PI3K inhibitor) or U0126 (a MAPK pathway inhibitor) before growth 
stimulation with serum or growth factors for LY294002 or serum for U0126. Inhibition of the PI3K pathway, but not the MAPK pathway, converted the 
expression profiles of Class II genes after serum treatment to a pattern similar to that after GF treatment.R42.10 Genome Biology 2006,     Volume 7, Issue 5, Article R42       Gu and Iyer  http://genomebiology.com/2006/7/5/R42
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functional groups of genes that are indicative of wound heal-
ing, although there were few individual genes commonly
induced in both studies.
The effect of different stresses, such as heat shock, ER stress,
oxidative stress and crowding stress, on lung fibroblasts have
been examined, and it was observed that the response to
endoplasmic reticulum (ER) stress caused by dithiothreitol
(DTT) was to some extent the opposite of the serum response
[46]. Indeed, we noted that some cell cycle control genes
showed differences between our experiments and the DTT
treatments. For example, p27 Kip1 (CDKN1B) was repressed
in our experiments in response to serum and GFs, but
induced by DTT treatment, while CKS2 and GSPT1 showed
the opposite behavior. At the same time, however, ER stress
induced several common immediate early response (IER)
genes, such as Jun-B, IER3, SNAIL, TNFAIP3, GADD45B,
and SPRY2, in the same manner as serum and GFs in the
experiments reported here, suggesting that the expression of
the these IERs are involved not only in cell proliferation in
fibroblasts, but also cell survival in response to DTT induced
stress.
Signaling pathways mediating transcriptional 
programs in fibroblasts
The concordant up or down regulation of a large set of genes
by distinct GF treatments as well as serum (Figure 1c,d) is
likely due to the fact that many different growth factor
receptors share a conserved intracellular receptor tyrosine
kinase (RTK) domain, which triggers similar downstream
events upon ligand (GF) binding. Global expression profiling
studies with chimeric receptor derivatives in mouse fibrob-
lasts indicate that the different intracellular signaling
domains of a growth factor receptor, although they may acti-
vate distinct signal transduction pathways, induce largely
overlapping sets of genes [24].
Despite the largely overlapping transcriptional response of
the different mitogenic treatments, we could identify
hundreds of genes that were differentially regulated when we
compared serum treatment with the other growth factors
(Class II genes, Figure 4). Since serum is a better cell prolifer-
ation stimulus than the other growth factors [47-49], we
firstly expected to see differences in the expression of cell
cycle related genes. Indeed, cyclin C and CDK6, which are
believed to be especially important in the G0 to G1 transition
of cells [4], are among the set of genes more strongly upregu-
lated by serum (Figure 6). However, the actual expression dif-
ferences of these two genes among the two groups are minor
and it is not clear how significant they are. Secondly, one
would expect to see differences in signaling pathways because
serum would be expected to activate not only growth factor
related RTKs, but also other cytokine RTKs or hormone
related G-protein coupled receptors. Indeed, we observed dif-
ferences in the expression of many genes involved in mediat-
ing the MAP kinase, PI3 kinase, DAG and G-coupled receptor
pathways. Interestingly, treatment with a PI3K pathway
inhibitor specifically reduced or eliminated most of these
differences, suggesting that the PI3K pathway has a more
prominent role in the response of fibroblasts to serum.
Conserved and specialized gene expression programs 
and regulation
The fibroblasts we used originated from different tissue
sources (skin and lung) and their slightly different transcrip-
tion profiles in response to mitogenic stimulation may partly
reflect their specialized physiological function in their tissue
Class III genes differentially expressed between skin and lung fibroblasts  during their transition from quiescence to proliferation Figure 7
Class III genes differentially expressed between skin and lung fibroblasts 
during their transition from quiescence to proliferation. (a) A cluster of 
385 genes differentially expressed between skin and lung fibroblasts, 
identified by using a t test and setting the FDR to 1%. (b) Average profiles 
of genes that were either highly expressed (red line) or repressed (green 
line) in skin fibroblasts relative to lung fibroblasts. The majority of Class III 
genes are in the former category and many of them reflect the higher 
proliferation rate of the skin fibroblasts.
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of origin. Anatomic origin-specific gene expression patterns
for these cells have been described before [6], but the expres-
sion of most of those genes did not vary during the prolifera-
tive response in our study. Out of the 358 genes that were
differentially expressed between the two cell types, around
one-quarter of the annotated genes were related to cell cycle
and signaling processes. The former group of genes reflects
the fact that the proliferation rate of the WI-38 lung fibrob-
lasts was considerably slower than that of the 2091 skin
fibroblasts.
The presence of a cluster of miRNAs induced during early
proliferation suggests that they may be involved in regulating
this transition in quiescent fibroblasts. Some of the miRNAs
in this cluster, such as miR-125b, miR-143, let-7 and miR-21,
have recently been discovered to be related to cell differentia-
tion, proliferation and apoptosis [50-53]. A role for miR-21
and let-7 in human fibroblast proliferation would be consist-
ent with the finding that a conditional knockout of the miRNA
processing enzyme dicer in mouse primary fibroblasts affects
the expression of miR-21  and  let-7, and slows down the
growth rate of fibroblasts [54]. The expression pattern of
these miRNAs in our study was well correlated with that of
genes encoding immediate early transcription factors, such as
c-Myc, SRF, JUNB, EGR2 and EGR3. Interestingly, c-Myc
and SRF are known to regulate the expression of some miR-
NAs [55,56]. The correlation between the expression profiles
of miRNAs and immediate-early transcription factors sug-
gests possible co-regulation of miRNAs and other regulators
by common immediate early transcription factors.
Our data support the existence of a conserved cell cycle gene
progression program and, surprisingly, a conserved wound
healing expression program among fibroblasts of distinct ori-
gins responding to distinct proliferative stimuli. Although tis-
sue specific differences exist between these two types of cells,
these specialized genes are, in general, not strongly respon-
sive to growth stimuli. It will be interesting to similarly study
commonalities and distinctions between growth-related
expression programs among cells of more diverse origins, and
dissect the contributions of individual regulatory proteins
and non-coding RNAs to such global expression programs.
Materials and methods
Cell culture and growth factor/inhibitor treatments
Normal human diploid foreskin fibroblast cell line 2091 and
lung fibroblasts WI-38 (ATCC, Manassas, VA, USA) at pas-
sage number 5 to 10 were used. Cells were cultured in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% FBS and 100 units penicillin-streptomycin. Unsyn-
chronized cells were normally growing cells at 80% to 90%
confluence. For serum starvation, cells were grown to about
60% confluence in 10 cm petri dishes and washed three times
with DMEM without serum. Low serum (0.1% FBS) DMEM
was then added to the dishes followed by a 48 h incubation.
Then, the medium was replaced by fresh DMEM with 10%
F B S  o r  D M E M  w i t h  0 . 1 %  F B S  p l u s  d i f f e r e n t  G F s .  G F s
(Upstate, Charlottesville, VA, USA) were prepared according
to supplier's instructions and added to the medium to a final
concentration of 50 ng/ml (EGF), 100 ng/ml (FGF) and 40
Expression profiles of miRNAs in skin fibroblasts Figure 8
Expression profiles of miRNAs in skin fibroblasts. (a) A cluster of 33 
miRNAs induced during early proliferation but repressed in 
asynchronously growing cells and late during proliferation. 10% serum was 
used in all these stimulation treatments except for one FGF (100 ng/ml) 
treatment as indicated. The colors representing ratios from the dye-swap 
experiments were inverted to be consistent with the non-dye swap 
samples. (b) Averaged expression level for each condition in the above 
clustering image.
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ng/ml (PDGF). For LY294002 treatment, serum starved 2091
cells were treated with 25 µM LY294002 (Promega, Madison,
WI, USA) for 30 minutes prior to GF or serum treatment.
Cells were collected right before LY294002 treatment, before
serum/GF stimulation (0 h) and 5 subsequent intervals (0.5,
1, 2, 4 and 8 h). For U0126 treatment, serum starved 2091
cells were treated with 10 µM U0126 (Promega) for 15 min-
utes prior to 10% serum treatment. Cells were collected at the
same time points as for LY294002.
RNA isolation and amplification
Total RNA was isolated with Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's instruc-
tions. Total RNA quantity and quality was determined by a
high-resolution electrophoresis system (Agilent Technolo-
gies, Palo Alto, CA, USA). Universal human reference RNA
(Stratagene, La Jolla, CA, USA) was used for the reference
channel in all hybridizations. RNA amplification was based
on the methodology developed at Stanford University [57]; 1
µg total RNA was co-denatured with 0.5 µg T7-oligo dT
primer (GCATTAGCGGCCGCGAAATTAATACGACTCAC-
TATAGGGAGA-(dT)21V) at 70°C for 5 minutes and then
chilled on ice. Reverse transcription was carried out in a 20 µl
reaction, containing 1 µl of SuperScript II (200 U/µl; Invitro-
gen), 1 µl RNase inhibitor (40 U/µl; Promega), 4 µl of 5x 1st
strand buffer, 2 µl of 0.1 M DTT, 1 µl diethylpyrocarbonate
(DEPC) treated water, and 1 µl of 10 mM dNTP mix (PE
Applied Biosystems, Foster City, CA, USA). After 2 hours
incubation, 2nd strand cDNA synthesis was carried out by
adding 2.5 µl Escherichia coli DNA polymerase I (10 U/µl;
NEB, Beverly, MA, USA), 1.5 µl E. coli DNA ligase (10 U/µl;
NEB), 1 µl RNase H (10 U/µl; Ambion, Austin, TX, USA), 3 µl
of 10 mM dNTP mix, 10 µl of 10x 2nd strand synthesis buffer,
and 62 µl DEPC-treated water. The reaction was incubated at
16°C for 2 hours, followed by DNA purification. 1 mg linear
acrylamide (Ambion) and 100 µl Phenol:Chloroform:Isoamyl
Alcohol (25:24:1; Invitrogen) were added to the reaction. The
aqueous phase was then isolated using phase lock gel (Eppen-
dorf, Hamburg, Germany) followed by the addition of 50 µl of
7.5 M ammonium acetate, and 375 µl of 100% ethanol. The
cDNA was precipitated immediately by centrifugation and
washed twice with 70% ethanol. The cDNA pellet was resus-
pended in 8 µl water and subject to in vitro transcription
using the T7 MegaScript kit (Ambion) followed by purifica-
tion using the RNeasy Mini kit (Qiagen, Hilden, Germany)
according to manufacturer's instructions.
microRNA preparation
Total RNA was isolated using either the mirVana miRNA Iso-
lation Kit (Ambion) or Trizol (Invitrogen) according to man-
ufacturers' instructions. A FlashPAGE fractionator (Ambion)
was used to isolate miRNA from total RNA. Briefly, 75 µg total
RNA sample was mixed with a dye and loaded onto a denatur-
ing acrylamide gel matrix. RNAs smaller than 40 nucleotides
were recovered after fractionation using the flashPAGE Reac-
tion Cleanup kit. The mirVana miRNA labeling Kit (Ambion)
was then used to label the enriched miRNAs. A mixture of
unmodified and amine-modified nucleotides were added to
the 3' end of each miRNA by poly(A) polymerase. The amine
group on the modified miRNA was coupled to NHS-ester
linked Cy5 or Cy3 dyes (GE Healthcare (formerly Amersham
Bioscience), Piscataway, NJ, USA). Unincorporated dyes
were removed with a glass fiber-based filter after a one hour
coupling reaction.
cDNA microarrays
We printed cDNA microarrays on poly L-lysine coated micro-
scope slides using a custom-built robotic arrayer. Each slide
was printed with about 47,000 sequence-verified IMAGE
clones (Research Genetics/Invitrogen). Labeled cDNA from 3
µg of Amplified Universal Human Reference total RNA and
amplified total RNA extracted from cells were used as the two
channels for each hybridization. The amino-allyl labeling and
hybridization protocols are described online [58]. Cy3 and
Cy5 labeled cDNAs were mixed with 10 µg human Cot-1 DNA,
5 µg polyA RNA, and 5 µg yeast tRNA (Invitrogen). Hybridi-
zations were performed in humidity chambers (Corning,
Corning, NY, USA) at 65°C for 16 hours. Slides were then
washed, dried, and scanned using an Axon GenePix 4000
scanner (Axon)
cDNA microarray data analysis
Microarray images were quantified using GenePix 4.0 soft-
ware (Axon). Data were uploaded to the Longhorn Array
Database as well as the Acuity 4.0 database (Axon). Array
normalization and spot filtering were done using Acuity. We
excluded spots with sum of median intensity less than 150 or
spots that had been flagged during visual gridding. For subse-
quent analysis, we used the log2 of the background sub-
tracted, normalized median spot intensities of ratios from the
two channels (Cy5/Cy3). Data were normalized in Acuity such
that the mean of the median of ratios of all good features
equaled 1.0. Data for each time course were then transformed
to show expression changes for each gene relative to the zero
time point, by dividing the median of ratios in the time zero
replicates from the corresponding data measured in each
time point. Three replicate time-courses were done for each
treatment and only genes with at least 80% of expression
measurements present were considered technically adequate
and were included in the subsequent analysis.
To identify consistently induced genes, we selected those with
more than twofold change (median of ratios) in at least 15
array experiments, which yielded 1,552 cDNA probes. After
removing cDNAs with no known Unigene annotation or those
that matched multiple Unigene clusters, we were left with
1,304 cDNAs that were subjected to hierarchical clustering.
By using average linkage clustering, two main clusters of
genes showing consistent induction (after removing two
small clusters of inconsistently varying genes) were picked for
further analysis, which contain 237 genes represented by 278
cDNA probes. Consistently repressed genes whose expressionhttp://genomebiology.com/2006/7/5/R42 Genome Biology 2006,     Volume 7, Issue 5, Article R42       Gu and Iyer  R42.13
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was reduced relative to the time zero samples in at least 85%
of the arrays were selected directly from the expression data.
This set with 237 genes represented by 250 cDNA probes was
then hierarchically clustered.
To identify genes differentially expressed between different
treatment groups (Class II and Class III genes), a Student's t-
test was performed and the FDR was calculated using the
Benjamini-Hochberg method in Acuity. For Class II genes,
the two groups were all the serum treated samples as one
group, and all the GF treated samples as another. For Class III
genes, the two groups were all the foreskin fibroblast samples
as one group and all the lung fibroblast samples as another.
Genes with FDR = 0.01 were considered expressed differently
between two groups. Hierarchical clustering was also done in
Acuity or by using Cluster and TreeView. Clones were queried
in the SOURCE database [59]. Unigene ID, gene symbol, and
GO annotation were thus obtained and used for functional
classification.
miRNA microarrays and analysis
DNA oligonucleotides corresponding to 206 miRNAs and
controls were purchased from Ambion. Sequences of these
miRNAs are provided in Additional data file 9. These probes
were resuspended in 3x saline sodium citrate (SSC) with
0.01% SDS at 50 µM and spotted on Nexterion epoxy Slide E
(Schott, Mainz, Germany) Slides were rehydrated and dried
normally, and were then blocked in a solution containing 100
mM ethanolamine, 1 M Tris (pH 9.0), and 0.1% SDS for 20
minutes at 50°C, then rinsed with water several times and
spun dry. Labeled miRNAs were mixed with 3x miRNA
hybridization buffer (Ambion) to 36 µl and heated at 95°C for
3 minutes. Slides were hybridized at 42°C for 14 to 16 hours
and scanned like the cDNA arrays described above. Image
gridding and preliminary analysis were done in GenePix Pro
5.0 (Axon). Data were then imported into Acuity 4.0 (Axon)
for further normalization and analysis. Normalization was
done by a ratio-based method. Generally, spots with intensity
lower than 150 or with median of ratios higher than 5 or lower
than 0.2 were excluded from the normalization. The ratio for
each spot was adjusted so that the overall mean of medians of
ratios equaled 1.0. Only those spots with intensity higher than
150 were selected for further analysis. Hierarchical clustering
was done using complete linkage with uncentered Pearson
correlation.
Western blot analysis
Quiescent 2091 and WI-38 cells were treated for 2 hours with
medium containing 10% FBS or 50 ng/ml EGF, 100 ng/ml
FGF and 40 ng/ml PDGF. Cell lysates (50 mg of protein) were
run on a 4% to 15% polyacrylamide gel (BioRad, Hercules, CA,
USA) and transferred to PVDF membrane (Millipore, Biller-
ica, MA, USA). The membrane was then blotted with the indi-
cated antibody and processed using chemiluminescence
(Santa Cruz, Santa Cruz, CA, USA). Antibodies used in this
experiment were anti-EGFR  (sc-03), anti-H-Ras  (sc-520)
and anti-ERBB2 (sc-7301), all from Santa Cruz Antibody. All
western blot experiments were performed at least three
times.
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 lists the expression
data of Class I genes. Additional data file 2 shows the DAVID
analysis of enriched GO categories within Class I, Class II and
Class III genes. Additional data file 3 is a histogram of expres-
sion peak timing. The graph shows the number of genes with
peak expression levels at each of the indicated times after
stimulation of quiescent cells, for each of the four treatments.
We calculated the peak time for each Class I gene (genes
induced by all treatments) for each time course. Data for skin
and lung fibroblasts were considered in combination. Since
we had two cell lines and three biological repeats of each time
course, for each GF treatment, we took the median time point
at which a gene showed its peak expression level. We then cal-
culated the percentage of genes peaking at each time point for
each treatment. EGF, FGF and PDGF tend to induce their
peak expression levels between 2 and 4 hours, but expression
peaks in response to serum are delayed up to 8 hours. Addi-
tional data file 4 shows the dose response of skin fibroblasts
to FGF. Skin fibroblasts were treated with the indicated con-
centrations of FGF for 2 hours. Higher concentrations
resulted in higher expression levels of induced genes, compa-
rable to the expression levels seen after treatment of the same
cells with serum. Data have been normalized to the time zero
sample value. However, although serum treatment resulted
in overall higher expression levels, their peaks of expression
were generally delayed as compared to FGF treatment. Addi-
tional data file 5 lists the expression data of Class II genes.
Additional data file 6 shows the tissue-specific gene expres-
sion in skin and lung fibroblasts. Relative gene expression
levels of quiescent skin fibroblasts and lung fibroblasts are
shown such that red indicates high expression in skin fibrob-
lasts and green indicates high expression in lung fibroblasts.
The right hand portion of the cluster shows data from this
study. Since a common universal reference sample was used
in all experiments, we divided the ratio of skin versus refer-
ence by the ratio of lung versus reference to obtain skin versus
lung data sets from a number of independent replicate exper-
iments. The left hand side shows comparative data from an
earlier study [6]. Additional data file 7 lists the expression
data of Class III genes. Additional data file 8 lists the expres-
sion data of miRNA genes. Additional data file 9 provides the
sequences of all miRNAs included on the miRNA microarray.
Additional File 1 Expression data of Class I genes Expression data of Class I genes Click here for file Additional File 2 DAVID analysis of enriched GO categories within Class I, Class II  and Class III genes DAVID analysis of enriched GO categories within Class I, Class II  and Class III genes Click here for file Additional File 3 Histogram of expression peak timing The graph shows the number of genes with peak expression levels  at each of the indicated times after stimulation of quiescent cells,  for each of the four treatments. We calculated the peak time for  each Class I gene (genes induced by all treatments) for each time  course. Data for skin and lung fibroblasts were considered in com- bination. Since we had two cell lines and three biological repeats of  each time course, for each GF treatment, we took the median time  point at which a gene showed its peak expression level. We then cal- culated the percentage of genes peaking at each time point for each  treatment. EGF, FGF and PDGF tend to induce their peak expres- sion levels between 2 and 4 hours, but expression peaks in response  to serum are delayed up to 8 hours. Click here for file Additional File 4 Dose response of skin fibroblasts to FGF Skin fibroblasts were treated with the indicated concentrations of  FGF for 2 hours. Higher concentrations resulted in higher expres- sion levels of induced genes, comparable to the expression levels  seen after treatment of the same cells with serum. Data have been  normalized to the time zero sample value. However, although  serum treatment resulted in overall higher expression levels, their  peaks of expression were generally delayed as compared to FGF  treatment Click here for file Additional File 5 Expression data of Class II genes Expression data of Class II genes Click here for file Additional File 6 Tissue-specific gene expression in skin and lung fibroblasts Relative gene expression levels of quiescent skin fibroblasts and  lung fibroblasts are shown such that red indicates high expression  in skin fibroblasts and green indicates high expression in lung  fibroblasts. The right hand portion of the cluster shows data from  this study. Since a common universal reference sample was used in  all experiments, we divided the ratio of skin versus reference by the  ratio of lung versus reference to obtain skin versus lung data sets  from a number of independent replicate experiments. The left hand  side shows comparative data from an earlier study [6] Click here for file Additional File 7 Expression data of Class III genes Expression data of Class III genes Click here for file Additional File 8 Expression data of miRNA genes Expression data of miRNA genes Click here for file Additional File 9 Sequences of all miRNAs included on the miRNA microarray Sequences of all miRNAs included on the miRNA microarray Click here for file
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